Results 51 to 60 of about 31,861 (267)
Objectives: To assess whether escalating to high-dose corticosteroids or anakinra compared with continuing low-dose corticosteroids reduced mortality in patients with severe COVID-19 whose respiratory function deteriorated while receiving dexamethasone 6
Annette Langer-Gould +9 more
doaj +1 more source
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition [PDF]
BACKGROUND:Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation.
Adams, BS +39 more
core
Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease [PDF]
Adult-onset Still's disease (AOSD) is a rare inflammatory disease of unknown etiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
Baggio, Chiara +4 more
core +1 more source
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen ...
Karolina Dahms +5 more
doaj +1 more source
Tocilizumab versus anakinra in COVID-19: results from propensity score matching
BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy ...
Robin Arcani +26 more
doaj +1 more source
Treatment of adult-onset Still's disease: a review [PDF]
Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. The former classification, based on the disease course, seems to be quite dated.
Gerfaud-Valentin, M. +3 more
core +3 more sources
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan +8 more
wiley +1 more source
Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis
Aim Anakinra, an anti IL-1 agent targeting IL-1 alfa and beta, is available for the treatment of recurrent pericarditis in cases with corticosteroid dependence and colchicine resistance after failure of conventional therapies.
Allan L Klein +14 more
doaj +1 more source
The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia
Cytokines such as IL-6, TNF-α and IL-1β trigger inflammatory cascades which may play a role in the pathogenesis of chronic kidney disease (CKD)-associated cachexia. CKD was induced by 5/6 nephrectomy in mice.
Wai W. Cheung +7 more
doaj +1 more source

